Tagasi

CEN/TS 17981-2:2023

In vitro diagnostic Next Generation Sequencing (NGS) workflows - Part 2: Human RNA examination

Üldinfo
Kehtiv alates 15.12.2023
Alusdokumendid
CEN/TS 17981-2:2023
Direktiivid või määrused
puuduvad

Standardi ajalugu

Staatus
Kuupäev
Tüüp
Nimetus
15.12.2023
Põhitekst
This document specifies requirements and gives recommendations for next generation sequencing (NGS) workflows for in vitro diagnostics and biomedical research. This document covers the pre-examination processes, human RNA isolation, sequencing library preparation, sequencing, sequence analysis and reporting of the examination of sequences for diagnostic purposes from isolated RNA from, e.g. formalin-fixed and paraffin embedded tissues, fresh frozen tissues, fine needle aspirates (FNA), whole blood, circulating tumour cells (CTCs), exosomes and other extracellular vesicles, and circulating cell free RNA from plasma.
NOTE 1  Typical applications include, but are not limited to, NGS for oncology and clinical genetics, certain single-cell analyses.
This document is applicable to molecular in vitro diagnostic examinations including laboratory developed tests performed by medical laboratories, molecular pathology laboratories and molecular genetic laboratories. This document is also applicable to laboratory customers, in vitro diagnostics developers and manufacturers, biobanks, institutions, and organisations performing biomedical research.
This document is not applicable for in situ sequencing, forensic sequencing, sequencing of pathogens or microorganisms and microbiome analysis.
NOTE 2  International, national or regional regulations or requirements or multiples of them can also apply to specific topics covered in this document.
*
*
*
PDF
28,06 € koos KM-ga
Paber
28,06 € koos KM-ga
Sirvi standardit alates 2,44 € koos KM-ga
Standardi monitooring